Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study

Autor: Jingqi Wang, Chunping Cui, Yaxin Lu, Yanyu Chang, Yuge Wang, Rui Li, Yilong Shan, Xiaobo Sun, Youming Long, Honghao Wang, Zhanhang Wang, Michael Lee, Shane He, Zhengqi Lu, Wei Qiu, Sha Tan
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Adult
Male
0301 basic medicine
medicine.medical_specialty
Immunology
acute attack
03 medical and health sciences
0302 clinical medicine
Neurofilament Proteins
Recurrence
T-Lymphocyte Subsets
Interquartile range
Internal medicine
medicine
Humans
Immunology and Allergy
Prospective Studies
Stage (cooking)
Expanded Disability Status Scale
biology
business.industry
Neuromyelitis Optica
Patient Acuity
expanded disability status scale
Disease Management
Interleukin
biomarkers
Middle Aged
RC581-607
Clinical Trial
Clinical trial
Treatment Outcome
030104 developmental biology
Disease Progression
biology.protein
Cytokines
Biomarker (medicine)
Female
Observational study
Disease Susceptibility
prognosis
Symptom Assessment
Antibody
neuromyelitis optica spectrum disorders
Immunologic diseases. Allergy
business
030217 neurology & neurosurgery
Zdroj: Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
ISSN: 1664-3224
Popis: ObjectiveTo explore the outcomes of NMOSD attacks and investigate serum biomarkers for prognosis and severity.MethodPatients with NMOSD attacks were prospectively and observationally enrolled from January 2019 to December 2020 at four hospitals in Guangzhou, southern China. Data were collected at attack, discharge and 1/3/6 months after acute treatment. Serum cytokine/chemokine and neurofilament light chain (NfL) levels were examined at the onset stage.ResultsOne hundred patients with NMOSD attacks were included. The treatment comprised intravenous methylprednisolone pulse therapy alone (IVMP, 71%), IVMP combined with apheresis (8%), IVMP combined with intravenous immunoglobulin (18%) and other therapies (3%). EDSS scores decreased significantly from a medium of 4 (interquartile range 3.0–5.5) at attack to 3.5 (3.0–4.5) at discharge, 3.5 (2.0–4.0) at the 1-month visit and 3.0 (2.0–4.0) at the 3-month visit (p2 = 0.487).ConclusionsOutcomes of NMOSD attacks were generally moderate. A high level of serum Th2-related cytokines predicted remission at the 1-month visit, and serum NfL may serve as a biomarker of disease severity at attack.Clinical Trial Registrationhttps://clinicaltrials.gov/ct2/show/NCT04101058, identifier NCT04101058.
Databáze: OpenAIRE
Externí odkaz: